Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study.
BRAF mutation
PD-L1
immune checkpoint inhibitors
non-small cell lung cancer
targeted therapy
Journal
Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
26
03
2022
received:
14
01
2022
accepted:
29
03
2022
pubmed:
10
4
2022
medline:
14
7
2022
entrez:
9
4
2022
Statut:
ppublish
Résumé
The incidence of primary and acquired BRAF mutations is low in non-small cell lung cancer (NSCLC), with limited demographic and treatment outcome data available for this patient population. We evaluated lung cancer samples with programmed cell death ligand 1 (PD-L1) information extracted from 12 051 cases (cohort A) of lung cancer from OncoPanscan™-based sequencing of tissue (Genetron Health) and conducted retrospective multicenter data analysis using the database of Zhejiang Cancer Hospital and four other centers (cohort B, including 73 primary BRAF mutation and 14 acquired BRAF mutation cases) to compare treatment outcomes of patient groups with primary and acquired BRAF mutations. In cohort A, after propensity score analysis, 165 samples of NSCLC with BRAF mutations were screened along with 165 paired non-BRAF mutation samples. We observed no significant differences in the proportion of samples with ≥1% PD-L1 between BRAF and non-BRAF mutant groups. The median progression-free survival (mPFS) period in 13 patients with primary BRAF mutations receiving BRAF tyrosine kinase inhibitors (BRAF-TKIs) was 7.0 months. The group with primary BRAF mutations receiving immune checkpoint inhibitor (ICI) combination chemotherapy had better PFS than those administered ICI monotherapy (14.77 months vs. 5.0 months, p = 0.025) and similar results were obtained for OS (unreached vs. 20.3 months, p = 0.013). For acquired BRAF mutations, mPFS of BRAF-TKI, ICI-based, and chemotherapy-based regimens were 3.8, 1.5, and 1.9 months, respectively. Therefore, for patients with the primary BRAF V600E mutation, targeted therapy or immunochemotherapy could serve as effective treatment choices, while for those with acquired BRAF V600E, targeted drug therapy may remain the preferred solution in China.
Substances chimiques
B7-H1 Antigen
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
530-541Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121-128. doi:10.1016/S1470-2045(09)70364-X
Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-1971. doi:10.1056/NEJMoa1406766
Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829-838. doi:10.1056/NEJMoa1704795
Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet. 2016;387:1415-1426. doi:10.1016/S0140-6736(16)00004-0
Salama AKS, Li S, Macrae ER, et al. Dabrafenib and Trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H. J Clin Oncol. 2020;38:3895-3904. doi:10.1200/JCO.20.00762
Koga T, Kobayashi Y, Tomizawa K, et al. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: an in vitro study. Lung Cancer. 2018;126:72-79. doi:10.1016/j.lungcan.2018.10.019
Farago AF, Le LP, Zheng Z, et al. Durable clinical response to Entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol. 2015;10(12):1670-1674. doi:10.1097/01.JTO.0000473485.38553.f0
Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19:4532-4540. doi:10.1158/1078-0432.CCR-13-0657
Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726-736. doi:10.1056/NEJMoa1502309
Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307-1316. doi:10.1016/S1470-2045(17)30679-4
Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:642-650. doi:10.1016/S1470-2045(16)00077-2
Solassol J, Vendrell JA, Senal R, Audran P, Leenhardt F, Quantin X. Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies. Lung Cancer. 2019;133:45-47. doi:10.1016/j.lungcan.2019.05.003
Meng P, Koopman B, Kok K, et al. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation. Lung Cancer. 2020;146:358-361. doi:10.1016/j.lungcan.2020.05.036
Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ, Chih-Hsin Yang J. Acquired BRAF V600E mutation as resistant mechanism after treatment with Osimertinib. J Thorac Oncol. 2017;12(3):567-572. doi:10.1016/j.jtho.2016.11.2231
Awad MM, Gadgeel SM, Borghaei H, et al. Long-term overall survival from KEYNOTE-021 cohort G: Pemetrexed and carboplatin with or without Pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. J Thorac Oncol. 2021;16:162-168. doi:10.1016/j.jtho.2020.09.015
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639. doi:10.1056/NEJMoa1507643
Arrieta O, Barrón F, Ramírez-Tirado LA, et al. Efficacy and safety of Pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial. JAMA Oncol. 2020;6:856-864. doi:10.1001/jamaoncol.2020.0409
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265. doi:10.1016/S0140-6736(16)32517-X
Lisberg A, Cummings A, Goldman JW, et al. A phase II study of Pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor Naïve patients with advanced NSCLC. J Thorac Oncol. 2018;13:1138-1145. doi:10.1016/j.jtho.2018.03.035
Dudnik E, Peled N, Nechushtan H, et al. BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors. J Thorac Oncol. 2018;13:1128-1137. doi:10.1016/j.jtho.2018.04.024
Guisier F, Dubos-Arvis C, Viñas F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018. J Thorac Oncol. 2020;15:628-636. doi:10.1016/j.jtho.2019.12.129
Travis WD, Brambilla E, Burke AP, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. International Agency for Research on Cancer; 2015:9-96.
Auliac JB, Bayle S, Do P, et al. Efficacy of Dabrafenib plus Trametinib combination in patients with BRAF V600E-mutant NSCLC in real-world setting: GFPC 01-2019. Cancers (Basel). 2020;12:3608. doi:10.3390/cancers12123608
Horn L, Bauml J, Forde PM, et al. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Lung Cancer. 2019;128:74-90. doi:10.1016/j.lungcan.2018.12.003
Galvano A, Gristina V, Malapelle U, et al. The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. ESMO Open. 2021;6:100124. doi:10.1016/j.esmoop.2021.100124
Gainor JF, Rizvi H, Jimenez Aguilar E, et al. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50. Ann Oncol. 2020;31:404-411. doi:10.1016/j.annonc.2019.11.015
Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30:1321-1328. doi:10.1093/annonc/mdz167
Dietel M, Savelov N, Salanova R, et al. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter EXPRESS study. Lung Cancer. 2019;134:174-179. doi:10.1016/j.lungcan.2019.06.012
Mu Y, Yang K, Hao X, et al. Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated non-small cell lung cancer. Front Oncol. 2020;10:603. doi:10.3389/fonc.2020.00603
Tan I, Stinchcombe TE, Ready NE, et al. Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study. Transl Lung Cancer Res. 2019;8:258-267. doi:10.21037/tlcr.2019.04.03
Di Federico A, De Giglio A, Parisi C, et al. PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: selecting the best strategy. Crit Rev Oncol Hematol. 2021;160:103302. doi:10.1016/j.critrevonc.2021.103302
Ding H, Zhuang Z, Xie J, Huang H, Tao Z, Liu Z. Durable clinical response of advanced lung adenocarcinoma harboring EGFR-19del/T790M/BRAFV600E mutations after treating with Osimertinib and Dabrafenib plus Trametinib: a case report. Onco Targets Ther. 2020;13:7933-7939. doi:10.2147/OTT.S240775
Zhang CX, Zhang CY, Lin JM, Li Z, Wang H. Patients with BRAF-mutant NSCLC may not benefit from immune checkpoint inhibitors: a population-based study. JTO Clin Res Rep. 2020;1(1):1-4. doi:10.1016/j.jtocrr.2020.100006; https://www.sciencedirect.com/science/article/pii/S2666364320300060
Rihawi K, Giannarelli D, Galetta D, et al. BRAF mutant NSCLC and immune checkpoint inhibitors: results from a real-world experience. J Thorac Oncol. 2019;14:e57-e59. doi:10.1016/j.jtho.2018.11.036
Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7:387-401. doi:10.1016/S2213-2600(19)30084-0